Intra-Operative Positioning System (IOPS) and IOPS Visionary System
Centerline Biomedical · Decision date Oct 1, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 2026-10-01 for K263016, the Intra-Operative Positioning System (IOPS) and IOPS Visionary System, submitted by Centerline Biomedical of Warrensville Heights, Ohio. The application was received 08/28/2026 under regulation 870.1425, device classification name Computer, Diagnostic, Programmable, with primary product code DQK and subsequent codes DQX and DQY. The regulation medical specialty and 510(k) review panel are both Cardiovascular. SESE in a 510(k) pathway denotes clearance for marketing, not PMA approval.
The record describes the submission type as Special, states that it was not reviewed by a third party, is not a combination product, and that no Predetermined Change Control Plan was authorized. The listed summary document was not available in the public information, so the specific device components, any changed items relative to a predicate, and the basis for the equivalence determination remain unknown. The subsequent product codes DQX and DQY are listed without explanation of their relationship to the subject device. No clinical performance, indications for use, or postmarket obligations can be characterized from this record.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 1, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K263016
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Centerline Biomedical
- Product code
- DQK
- Decision code
- SESE
- Decision date
- Oct 1, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Computer, Diagnostic, Programmable.
- Applicant
- Centerline Biomedical
- Product code
- DQK
- FDA device class
- 2
FDA decision timeline
K263016 received
Application receipt date recorded by FDA.
K263016 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code DQK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Merge Healthcare Incorporated | 510(k) clearance | Nov 5, 2026 | FDA | |
VIVO (9002)K261886 | Catheter Precision, Inc. | 510(k) clearance | Oct 30, 2026 | FDA |
PulseAPI SmartWatchK254226 | PulseAI, Ltd. | 510(k) clearance | Oct 27, 2026 | FDA |
STAR Apollo Mapping SystemK263380 | Rhythm AI, Ltd. | 510(k) clearance | Oct 23, 2026 | FDA |
S-Patch CardioAIK254255 | Wellysis Corp. | 510(k) clearance | Sep 25, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Centerline Biomedical
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Warrensville Heights, OH
Sources and methodology
- Original FDA record: K263016
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

